Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
ophthalmology
Brought to you by:
Biotech
Boehringer pens $1B pact to reduce eye drug injections
Boehringer Ingelheim is continuing to explore its newfound interest in eye health, penning a $1 billion biobucks pact with Re-Vana Therapeutics.
James Waldron
Jul 28, 2025 8:48am
Okyo's eye drops reduce neuropathic eye pain in phase 2 win
Jul 16, 2025 11:57am
ForSight Robotics raises $125M to trial eye surgery platform
Jun 24, 2025 11:40am
Stuart sees dry eye disease drug fail ph. 3 study, plans another
Jun 24, 2025 9:26am
Atsena gene therapy hits safety goals, closes retinal splits
May 19, 2025 12:59pm
Beacon shines a light on positive early data from eye disease ph. 2
May 7, 2025 7:15am
